Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 2, 2012
Grant Date -
Dec 4, 2003
app pub date -
Mar 3, 2003
filing date -
Sep 4, 2000
priority date (Note) -
In Force
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
The invention describes the use of a pharmaceutical preparation containing a trifunctional bispecific and/or trispecific having the following properties:
- a) binding to a T cell;b) binding to at least an antigen on a tumor cell associated with malignant ascites and/or pleural effusion;c) binding, by its Fc portion (in the case of bispecific antibodies) or by a third specificity (in the case of trispecific antibodies), to Fc receptor-positive cells for the destruction of the tumor cells in the treatment of malignant ascites and/or pleural effusion.
Loading the Abstract Image...
OK
First Claim
Family
Loading Family data...
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully